β‑catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine‑resistant breast cancer cells

Ham,Ahrong; Cho,Min Hee; Won,Hye Sung; Jo,Jungmin; Lee,Kyoung Eun

doi:10.3892/or.2022.8341

β‑catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine‑resistant breast cancer cells

Authors:
- Ahrong Ham
- Min Hee Cho
- Hye Sung Won
- Jungmin Jo
- Kyoung Eun Lee
View Affiliations

Affiliations: Division of Hematology‑Oncology, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
Published online on: June 2, 2022 https://doi.org/10.3892/or.2022.8341
Article Number: 130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wnt/β‑catenin signaling is involved in endocrine resistance and stem cell‑like properties of hormone receptor‑positive breast cancer cells. Palbociclib is a well‑known inhibitor of cyclin‑dependent kinase 4 and 6 (CDK4/6 inhibitor) that downregulates the activation of retinoblastoma protein, thereby inhibiting the cell cycle in breast cancer cells. The inhibitory effects of a combination of palbociclib and ICG‑001, a β‑catenin small‑molecule inhibitor, were investigated in tamoxifen‑resistant breast cancer cell lines. Tamoxifen‑resistant MCF‑7 (TamR) cells were established by continuously exposing MCF‑7 cells to tamoxifen. The characteristics associated with the stem cell‑like property of cancer were assessed using western blotting, cell cycle analysis, and the mammosphere assay. The effects of the combination of palbociclib and ICG‑001 were evaluated in control MCF‑7 and TamR cell lines. Compared with control cells, TamR cells exhibited elevated levels of Nanog, Sox2, ALDH1, and p‑STAT3, indicating stem cell‑like characteristics, and elevated β‑catenin activity. TamR cells also showed significantly higher mammosphere‑forming efficiency. Several markers of stem cell‑like nature of TamR cells showed reduced levels upon treatment of cells with the drug combination; there was a greater reduction in the levels of these markers when the cells were treated with the combination than in the case where cells were treated with one of the drugs individually (combination index value for 25 µM palbociclib and 50 µM ICG‑001 was 1.1±0.02). TamR cells treated with the palbociclib and ICG‑001 combination demonstrated significantly reduced cell proliferation and mammosphere‑forming efficiency compared with the cells treated with one of these drugs. The combination of the drugs could additively inhibit proliferation and suppress stem cell‑like characteristics. These results suggest that β‑catenin plays a role in endocrine‑resistant breast cancer; the inhibition of β‑catenin and CDK4/6 together can overcome endocrine resistance in breast cancer cells.

View Figures

View References

1	Waks AG and Winer EP: Breast cancer treatment: A review. Jama. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
2	Murphy CG and Dickler MN: Endocrine resistance in hormone-responsive breast cancer: Mechanisms and therapeutic strategies. Endocr Relat Cancer. 23:R337–R352. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ziauddin MF, Hua D and Tang SC: Emerging strategies to overcome resistance to endocrine therapy for breast cancer. Cancer Metastasis Rev. 33:791–807. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mills JN, Rutkovsky AC and Giordano A: Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 41:59–65. 2018. View Article : Google Scholar : PubMed/NCBI
5	Won HS, Lee KM, Oh JE, Nam EM and Lee KE: Inhibition of β-catenin to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. PLoS One. 11:e01559832016. View Article : Google Scholar : PubMed/NCBI
6	Clarke R, Tyson JJ and Dixon JM: Endocrine resistance in breast cancer-An overview and update. Mol Cell Endocrinol. 418Pt:220–234. 2015. View Article : Google Scholar : PubMed/NCBI
7	Beaver JA and Park BH: The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 8:651–657. 2012. View Article : Google Scholar : PubMed/NCBI
8	Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 30:2718–2724. 2012. View Article : Google Scholar : PubMed/NCBI
9	Rodriguez D, Ramkairsingh M, Lin X, Kapoor A, Major P and Tang D: The central contributions of breast cancer stem cells in developing resistance to endocrine therapy in estrogen receptor (ER)-positive breast cancer. Cancers (Basel). 11:10282019. View Article : Google Scholar : PubMed/NCBI
10	Liu H, Zhang HW, Sun XF, Guo XH, He YN, Cui SD and Fan QX: Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties. Chin Med J (Engl). 126:3030–3034. 2013.PubMed/NCBI
11	Sakunrangsit N and Ketchart W: Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. Pharmacol Res. 150:1045172019. View Article : Google Scholar : PubMed/NCBI
12	Yin S, Cheryan VT, Xu L, Rishi AK and Reddy KB: Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 12:e01835782017. View Article : Google Scholar : PubMed/NCBI
13	Mukherjee N and Panda CK: Wnt/β-catenin signaling pathway as chemotherapeutic target in breast cancer: An update on pros and cons. Clin Breast Cancer. 20:361–370. 2020. View Article : Google Scholar : PubMed/NCBI
14	Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011. View Article : Google Scholar : PubMed/NCBI
15	Shang S, Hua F and Hu ZW: The regulation of β-catenin activity and function in cancer: Therapeutic opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
16	Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI
17	Vilchez V, Turcios L, Marti F and Gedaly R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
18	Liu F, Xia Z, Zhang M, Ding J, Feng Y, Wu J, Dong Y, Gao W, Han Z, Liu Y, et al: SMARCAD1 promotes pancreatic cancer cell growth and metastasis through Wnt/β-catenin-mediated EMT. Int J Biol Sci. 15:636–646. 2019. View Article : Google Scholar : PubMed/NCBI
19	Liu Y, Chen H, Zheng P, Zheng Y, Luo Q, Xie G, Ma Y and Shen L: ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 36:1252017. View Article : Google Scholar : PubMed/NCBI
20	Yin P, Wang W, Zhang Z, Bai Y, Gao J and Zhao C: Wnt signaling in human and mouse breast cancer: Focusing on wnt ligands, receptors and antagonists. Cancer Sci. 109:3368–3375. 2018. View Article : Google Scholar : PubMed/NCBI
21	Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bilir B, Kucuk O and Moreno CS: Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 11:2802013. View Article : Google Scholar : PubMed/NCBI
23	Lv C, Li F, Li X, Tian Y, Zhang Y, Sheng X, Song Y, Meng Q, Yuan S, Luan L, et al: MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat Commun. 8:10362017. View Article : Google Scholar : PubMed/NCBI
24	Katoh M: Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β-catenin signaling activation (Review). Int J Mol Med. 42:713–725. 2018.PubMed/NCBI
25	Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR and Dawson DW: The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther. 13:2303–2314. 2014. View Article : Google Scholar : PubMed/NCBI
26	Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, et al: Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer. Genome Med. 10:542018. View Article : Google Scholar : PubMed/NCBI
27	Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, et al: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
28	Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 35:2875–2884. 2017. View Article : Google Scholar : PubMed/NCBI
29	Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 36:2465–2472. 2018. View Article : Google Scholar : PubMed/NCBI
30	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
31	Bijnsdorp IV, Giovannetti E and Peters GJ: Analysis of drug interactions. Methods Mol Biol. 731:421–434. 2011. View Article : Google Scholar : PubMed/NCBI
32	Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
33	Kim JW, Gautam J, Kim JE, Kim JA and Kang KW: Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor. Oncol Lett. 17:3981–3989. 2019.PubMed/NCBI
34	Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, Wang Y, Lu N, Zhu H and Xu N: beta-catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 271:85–97. 2008. View Article : Google Scholar : PubMed/NCBI
35	Armanious H, Gelebart P, Mackey J, Ma Y and Lai R: STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol. 3:654–664. 2010.PubMed/NCBI
36	Huang R, Wang S, Wang N, Zheng Y, Zhou J, Yang B, Wang X, Zhang J, Guo L, Wang S, et al: CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling. Cell Death Dis. 11:2342020. View Article : Google Scholar : PubMed/NCBI
37	Kawasaki K, Kuboki S, Furukawa K, Takayashiki T, Takano S and Ohtsuka M: LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. Liver Int. 41:865–881. 2021. View Article : Google Scholar : PubMed/NCBI
38	Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, et al: Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. 25:3996–4013. 2019. View Article : Google Scholar : PubMed/NCBI